{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:31:13Z","timestamp":1760239873674,"version":"build-2065373602"},"reference-count":44,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T00:00:00Z","timestamp":1609372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Molecular targeting of growth factors has shown great therapeutic potential in pharmaceutical research due to their roles in pathological conditions. In the present study, we developed a novel suramin fragment and deoxycholic acid conjugate (SFD) that exhibited the potential to bind to the heparin-binding site (HBD) of vascular endothelial growth factor (VEGF) and to inhibit its pathogenic action for the first time. Notably, SFD was optimally designed for binding to the HBD of VEGF using the naphthalenetrisulfonate group, allowing to observe its excellent binding efficacy in a surface plasmon resonance (SPR) study, showing remarkable binding affinity (KD = 3.8 nM) as a small molecule inhibitor. In the tubular formation assay, it was observed that SFD could bind to HBD and exhibit antiangiogenic efficacy by inhibiting VEGF, such as heparins. The cellular treatment of SFD resulted in VEGF-inhibitory effects in human umbilical vein endothelial cells (HUVECs). Therefore, we propose that SFD can be employed as a novel drug candidate to inhibit the pathophysiological action of VEGF in diseases. Consequently, SFD, which has a molecular structure optimized for binding to HBD, is put forward as a new chemical VEGF inhibitor.<\/jats:p>","DOI":"10.3390\/biom11010046","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T10:10:37Z","timestamp":1609409437000},"page":"46","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Molecular Targeting of VEGF with a Suramin Fragment\u2013DOCA Conjugate by Mimicking the Action of Low Molecular Weight Heparins"],"prefix":"10.3390","volume":"11","author":[{"given":"Jooho","family":"Park","sequence":"first","affiliation":[{"name":"Department of Biomedical Chemistry, College of Biomedical &amp; Health Science, Konkuk University, Chungju 27478, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1441-9470","authenticated-orcid":false,"given":"Tae-Bong","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, College of Biomedical &amp; Health Science, Konkuk University, Chungju 27478, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Hong","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Biomedical Chemistry, College of Biomedical &amp; Health Science, Konkuk University, Chungju 27478, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyung-Sik","family":"Won","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, College of Biomedical &amp; Health Science, Konkuk University, Chungju 27478, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: Therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Jena, M.K., Sharma, N.R., Petitt, M., Maulik, D., and Nayak, N.R. (2020). Pathogenesis of Preeclampsia and Therapeutic Approaches Targeting the Placenta. Biomolecules, 10.","DOI":"10.3390\/biom10060953"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.4161\/cc.24579","article-title":"The p53 family and VEGF regulation: \u201cIt\u2019s complicated\u201d","volume":"12","author":"Goossens","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3389\/fonc.2019.01399","article-title":"Contribution of Angiogenesis to Inflammation and Cancer","volume":"9","year":"2019","journal-title":"Front. Oncol"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/154405910708601005","article-title":"Angiogenesis inhibitors and the need for anti-angiogenic therapeutics","volume":"86","author":"Dass","year":"2007","journal-title":"J. Dent. Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Park, J.Y., Ji, Y.S., Zhu, H., Zhang, Y., Park, D.H., Kim, Y.J., Yoo, H.H., and Kang, K.S. (2019). Anti-Angiogenic Effect of Asperchalasine A via Attenuation of VEGF Signaling. Biomolecules, 9.","DOI":"10.3390\/biom9080358"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ko, J.H., Kwon, H.S., Kim, B., Min, G., Shin, C., Yang, S.W., Lee, S.W., Lee, Y., Hong, D., and Kim, Y.S. (2020). Preclinical Efficacy and Safety of an Anti-Human VEGFA and Anti-Human NRP1 Dual-Targeting Bispecific Antibody (IDB0076). Biomolecules, 10\n\t\t  .","DOI":"10.3390\/biom10060919"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"38080","DOI":"10.18632\/oncotarget.17373","article-title":"Sales for anti-angiogenic drugs","volume":"8","author":"Ribatti","year":"2017","journal-title":"Oncotarget"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1126\/science.6192498","article-title":"Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone","volume":"221","author":"Folkman","year":"1983","journal-title":"Science"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/1521-3773(20020201)41:3<390::AID-ANIE390>3.0.CO;2-B","article-title":"Heparin-protein interactions","volume":"41","author":"Capila","year":"2002","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_11","first-page":"1435","article-title":"In vivo biodistribution of topical low molecular weight heparin-taurocholate in a neovascularized mouse cornea","volume":"11","author":"Moon","year":"2018","journal-title":"Int. J. Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijpharm.2017.10.055","article-title":"Self-assembled nanocomplex of PEGylated protamine and heparin-suramin conjugate for accumulation at the tumor site","volume":"535","author":"Park","year":"2018","journal-title":"Int. J. Pharm"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"075102","DOI":"10.1088\/1361-6528\/aa53c6","article-title":"Anti-angiogenic activity and antitumor efficacy of amphiphilic twin drug from ursolic acid and low molecular weight heparin","volume":"28","author":"Cheng","year":"2017","journal-title":"Nanotechnology"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Furukawa, K., Nagano, T., Tachihara, M., Yamamoto, M., and Nishimura, Y. (2020). Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer. Molecules, 25.","DOI":"10.3390\/molecules25173900"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s13233-016-4111-8","article-title":"Antiangiogenic actions of heparin derivatives for cancer therapy","volume":"24","author":"Hwang","year":"2016","journal-title":"Macromol Res."},{"key":"ref_16","first-page":"9780489","article-title":"Heparin-Based Nanoparticles: An Overview of Their Applications","volume":"2018","year":"2018","journal-title":"J. Nanomater."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1182\/blood.2019000510","article-title":"The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing","volume":"133","author":"Ishihara","year":"2019","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Dubashynskaya, N., Poshina, D., Raik, S., Urtti, A., and Skorik, Y.A. (2020). Polysaccharides in Ocular Drug Delivery. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12010022"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/19336918.2020.1767489","article-title":"The anti-cancer properties of heparin and its derivatives: A review and prospect","volume":"14","author":"Ma","year":"2020","journal-title":"Cell Adhes. Migr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0165-6147(00)89022-7","article-title":"Therapeutic uses of heparin beyond its traditional role as an anticoagulant","volume":"16","author":"Tyrell","year":"1995","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ejca.2015.02.007","article-title":"PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples","volume":"51","author":"Winterhoff","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1200\/JCO.1989.7.4.499","article-title":"Suramin\u2014An Anticancer Drug with a Unique Mechanism of Action","volume":"7","author":"Stein","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1006\/jmcc.1996.0142","article-title":"Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action","volume":"28","author":"Waltenberger","year":"1996","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1021\/bi051389b","article-title":"Understanding the mechanism of the antimitogenic activity of suramin","volume":"45","author":"Kathir","year":"2006","journal-title":"Biochemistry"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"10757","DOI":"10.1021\/bi050401x","article-title":"Structural basis for antagonism by suramin of heparin binding to vaccinia complement protein","volume":"44","author":"Ganesh","year":"2005","journal-title":"Biochemistry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ana.21429","article-title":"The continuing problem of human African trypanosomiasis (sleeping sickness)","volume":"64","author":"Kennedy","year":"2008","journal-title":"Ann. Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1016\/j.tet.2009.03.033","article-title":"An \u2018inside-out\u2019 approach to suramin analogues","volume":"65","author":"McGeary","year":"2009","journal-title":"Tetrahedron"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1016\/j.bmcl.2017.08.013","article-title":"Arylamidonaphtalene sulfonate compounds as a novel class of heparanase inhibitors","volume":"27","author":"Rondanin","year":"2017","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"von der Ahe, D., Huehnchen, P., Balkaya, M., Peruzzaro, S., Endres, M., and Boehmerle, W. (2018). Suramin-Induced Neurotoxicity: Preclinical Models and Neuroprotective Strategies. Molecules, 23.","DOI":"10.3390\/molecules23020346"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.biomaterials.2017.05.026","article-title":"A heparin conjugate, LHbisD4, inhibits lymphangiogenesis and attenuates lymph node metastasis by blocking VEGF-C signaling pathway","volume":"139","author":"Choi","year":"2017","journal-title":"Biomaterials"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1172\/JCI83427","article-title":"Targeting prion-like protein doppel selectively suppresses tumor angiogenesis","volume":"126","author":"Chung","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","article-title":"Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date","volume":"33","author":"Bobo","year":"2016","journal-title":"Pharm. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/MOH.0000000000000168","article-title":"Updates in pediatric venous thromboembolism","volume":"22","author":"Gillespie","year":"2015","journal-title":"Curr. Opin. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1021\/acs.bioconjchem.5b00133","article-title":"Size Controlled Heparin Fragment-Deoxycholic Acid Conjugate Showed Anticancer Property by Inhibiting VEGF165","volume":"26","author":"Park","year":"2015","journal-title":"Bioconjugate Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1021\/acs.molpharmaceut.5b00348","article-title":"Chemical Conjugate of Low Molecular Weight Heparin and Suramin Fragment Inhibits Tumor Growth Possibly by Blocking VEGF165","volume":"12","author":"Park","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0969-2126(98)00065-3","article-title":"Solution structure of the heparin-binding domain of vascular endothelial growth factor","volume":"6","author":"Fairbrother","year":"1998","journal-title":"Struct. Fold. Des."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1021\/acs.jcim.9b00778","article-title":"Autodock Vina Adopts More Accurate Binding Poses but Autodock4 Forms Better Binding Affinity","volume":"60","author":"Nguyen","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0003-2697(91)90424-R","article-title":"Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors","volume":"198","author":"Johnsson","year":"1991","journal-title":"Anal. Biochem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1042\/BSR20110077","article-title":"Binding affinities of vascular endothelial growth factor (VEGF) for heparin-derived oligosaccharides","volume":"32","author":"Zhao","year":"2012","journal-title":"Biosci. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jconrel.2010.09.014","article-title":"High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives","volume":"148","author":"Park","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s11095-006-9139-6","article-title":"Antiangiogenic effect of bile acid acylated heparin derivative","volume":"24","author":"Park","year":"2007","journal-title":"Pharm. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1002\/ijc.24239","article-title":"Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor","volume":"124","author":"Lee","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.actbio.2018.12.010","article-title":"Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles","volume":"84","author":"Cheng","year":"2019","journal-title":"Acta Biomater."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/11\/1\/46\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:48:29Z","timestamp":1760179709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/11\/1\/46"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,31]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["biom11010046"],"URL":"https:\/\/doi.org\/10.3390\/biom11010046","relation":{},"ISSN":["2218-273X"],"issn-type":[{"type":"electronic","value":"2218-273X"}],"subject":[],"published":{"date-parts":[[2020,12,31]]}}}